Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib with chemotherapy and sequential radiotherapy in first-line limited-stage small cell lung cancer
ChiCTR2600123265Phase 4Completed
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of trilaciclib in small cell lung cancer (SCLC) (2 arms), sponsored by Liaoning Province Cancer Hospital. Primary endpoint: Incidence of grade ≥ 3 neutropenia during chemotherapy treatment. Started Apr 2026; status: completed.
02
Drugs
trilaciclib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2600123265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123265.